Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.48
NYSE:WAT's Cash to Debt is ranked lower than
51% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NYSE:WAT: 1.48 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:WAT' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 1.1 Max: 336.71
Current: 1.48
0
336.71
Equity to Asset 0.48
NYSE:WAT's Equity to Asset is ranked lower than
68% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NYSE:WAT: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:WAT' s Equity to Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.45 Max: 0.7
Current: 0.48
0.11
0.7
Interest Coverage 14.79
NYSE:WAT's Interest Coverage is ranked lower than
62% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NYSE:WAT: 14.79 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:WAT' s Interest Coverage Range Over the Past 10 Years
Min: 5.71  Med: 16.44 Max: 35.92
Current: 14.79
5.71
35.92
F-Score: 5
Z-Score: 6.61
M-Score: -2.54
WACC vs ROIC
7.35%
39.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.70
NYSE:WAT's Operating margin (%) is ranked higher than
94% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NYSE:WAT: 27.70 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:WAT' s Operating margin (%) Range Over the Past 10 Years
Min: 23.05  Med: 26.75 Max: 28.55
Current: 27.7
23.05
28.55
Net-margin (%) 23.33
NYSE:WAT's Net-margin (%) is ranked higher than
93% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NYSE:WAT: 23.33 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:WAT' s Net-margin (%) Range Over the Past 10 Years
Min: 17.36  Med: 22.34 Max: 25.03
Current: 23.33
17.36
25.03
ROE (%) 23.97
NYSE:WAT's ROE (%) is ranked higher than
93% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NYSE:WAT: 23.97 )
Ranked among companies with meaningful ROE (%) only.
NYSE:WAT' s ROE (%) Range Over the Past 10 Years
Min: 23.6  Med: 38.77 Max: 68.79
Current: 23.97
23.6
68.79
ROA (%) 11.53
NYSE:WAT's ROA (%) is ranked higher than
85% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NYSE:WAT: 11.53 )
Ranked among companies with meaningful ROA (%) only.
NYSE:WAT' s ROA (%) Range Over the Past 10 Years
Min: 11.52  Med: 15.5 Max: 18.41
Current: 11.53
11.52
18.41
ROC (Joel Greenblatt) (%) 79.68
NYSE:WAT's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NYSE:WAT: 79.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:WAT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 72.34  Med: 86.76 Max: 99.06
Current: 79.68
72.34
99.06
Revenue Growth (3Y)(%) 5.90
NYSE:WAT's Revenue Growth (3Y)(%) is ranked higher than
57% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NYSE:WAT: 5.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:WAT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.2  Med: 8.9 Max: 17.8
Current: 5.9
5.2
17.8
EBITDA Growth (3Y)(%) 7.00
NYSE:WAT's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NYSE:WAT: 7.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:WAT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.4  Med: 11 Max: 69.2
Current: 7
2.4
69.2
EPS Growth (3Y)(%) 2.90
NYSE:WAT's EPS Growth (3Y)(%) is ranked lower than
57% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NYSE:WAT: 2.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:WAT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.6  Med: 14.6 Max: 79.9
Current: 2.9
2.6
79.9
» NYSE:WAT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

WAT Guru Trades in Q3 2015

Jim Simons 294,800 sh (+157.05%)
Ray Dalio 8,904 sh (+142.95%)
John Hussman 20,000 sh (unchged)
Ruane Cunniff 2,038,353 sh (-0.59%)
Chuck Royce 14,437 sh (-6.56%)
PRIMECAP Management 657,721 sh (-7.59%)
Paul Tudor Jones 5,300 sh (-8.43%)
Jeremy Grantham 54,090 sh (-57.91%)
Joel Greenblatt 25,527 sh (-71.35%)
» More
Q4 2015

WAT Guru Trades in Q4 2015

Jim Simons 296,696 sh (+0.64%)
Chuck Royce 14,437 sh (unchged)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
PRIMECAP Management 651,117 sh (-1.00%)
Ruane Cunniff 1,995,247 sh (-2.11%)
John Hussman 15,000 sh (-25.00%)
Jeremy Grantham 36,790 sh (-31.98%)
Paul Tudor Jones 3,200 sh (-39.62%)
» More
Q1 2016

WAT Guru Trades in Q1 2016

Joel Greenblatt 24,086 sh (New)
John Hussman Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 650,867 sh (-0.04%)
Ruane Cunniff 1,920,738 sh (-3.73%)
Chuck Royce 11,387 sh (-21.13%)
Jim Simons 169,200 sh (-42.97%)
Jeremy Grantham 2,109 sh (-94.27%)
» More
Q2 2016

WAT Guru Trades in Q2 2016

Paul Tudor Jones 2,800 sh (New)
Louis Moore Bacon 18,000 sh (New)
Ray Dalio 2,600 sh (New)
Pioneer Investments 8,690 sh (New)
Joel Greenblatt 105,556 sh (+338.25%)
Jeremy Grantham Sold Out
Jim Simons Sold Out
PRIMECAP Management 628,667 sh (-3.41%)
Ruane Cunniff 1,770,014 sh (-7.85%)
Chuck Royce 5,047 sh (-55.68%)
» More
» Details

Insider Trades

Latest Guru Trades with WAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:OCPNY, NAS:XRAY, NYSE:MTD, NAS:HOLX, OTCPK:TRUMY, OTCPK:CLPBY, NYSE:RMD, NYSE:COO, NYSE:BCR, NYSE:STE, NAS:SIRO, OTCPK:SAUHF, NYSE:WST, OTCPK:GNGBY, NYSE:HRC, NYSE:CMN, OTCPK:ANSLF, NAS:PODD, NAS:ICUI, NYSE:HAE » details
Traded in other countries:WAZ.Germany,
Waters Corp is an analytical instrument manufacturer, that designs, manufactures, sells and services liquid chromatography, ultra performance liquid chromatography & mass spectrometry instrument systems & support products.

Waters Corp was incorporated in Delaware in 1991. It is an analytical instrument manufacturer, mainly designs, manufactures, sells and services, through its Waters Division, high performance liquid chromatography, ultra performance liquid chromatography and mass spectrometry instrument systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. Waters became a publicly-traded company with its initial public offering ("IPO") in November 1995. The Company's two operating segments, Waters Division and TA Division, have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution and regulatory environments. The Waters Division's products and services consist of high performance liquid chromatography ("HPLC"), ultra performance liquid chromatography ("UPLC" and together with HPLC, referred to as "LC"), mass spectrometry ("MS") and chemistry consumable products and related services. TA products and services consist of thermal analysis, rheometry and calorimetry instrument systems and service sales. The Company's products are used by pharmaceutical, life science, biochemical, industrial, nutritional safety, environmental, academic and governmental customers. These customers use the Company's products to detect, identify, monitor and measure the chemical, physical and biological composition of materials and to predict the suitability of fine chemicals, pharmaceuticals, water, polymers and viscous liquids in various industrial, consumer goods and healthcare products. The Company's competitors include: Agilent Technologies, Inc., Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc. In the markets served by the TA Division, the Company's principal competitors include: PerkinElmer, Inc., Mettler-Toledo International Inc., NETZSCH-Geraetebau GmbH, Thermo Fisher Scientific Inc., Malvern Instruments Ltd., Anton-Paar and General Electric Company.

Ratios

vs
industry
vs
history
P/E(ttm) 26.58
WAT's P/E(ttm) is ranked higher than
58% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.50 vs. WAT: 26.58 )
Ranked among companies with meaningful P/E(ttm) only.
WAT' s P/E(ttm) Range Over the Past 10 Years
Min: 9.64  Med: 20.93 Max: 32.25
Current: 26.58
9.64
32.25
Forward P/E 21.93
WAT's Forward P/E is ranked higher than
60% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.70 vs. WAT: 21.93 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.58
WAT's PE(NRI) is ranked higher than
55% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.80 vs. WAT: 26.58 )
Ranked among companies with meaningful PE(NRI) only.
WAT' s PE(NRI) Range Over the Past 10 Years
Min: 9.64  Med: 20.93 Max: 32.25
Current: 26.58
9.64
32.25
Price/Owner Earnings (ttm) 26.93
WAT's Price/Owner Earnings (ttm) is ranked higher than
54% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.25 vs. WAT: 26.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
WAT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.12  Med: 22.18 Max: 34.46
Current: 26.93
10.12
34.46
P/B 5.89
WAT's P/B is ranked lower than
75% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. WAT: 5.89 )
Ranked among companies with meaningful P/B only.
WAT' s P/B Range Over the Past 10 Years
Min: 4.38  Med: 6.31 Max: 19.91
Current: 5.89
4.38
19.91
P/S 6.19
WAT's P/S is ranked lower than
76% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. WAT: 6.19 )
Ranked among companies with meaningful P/S only.
WAT' s P/S Range Over the Past 10 Years
Min: 2.06  Med: 4.43 Max: 6.29
Current: 6.19
2.06
6.29
PFCF 25.95
WAT's PFCF is ranked higher than
57% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. WAT: 25.95 )
Ranked among companies with meaningful PFCF only.
WAT' s PFCF Range Over the Past 10 Years
Min: 9.71  Med: 21.28 Max: 30.1
Current: 25.95
9.71
30.1
POCF 21.43
WAT's POCF is ranked lower than
59% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. WAT: 21.43 )
Ranked among companies with meaningful POCF only.
WAT' s POCF Range Over the Past 10 Years
Min: 7.86  Med: 17.35 Max: 24.72
Current: 21.43
7.86
24.72
EV-to-EBIT 20.03
WAT's EV-to-EBIT is ranked higher than
56% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. WAT: 20.03 )
Ranked among companies with meaningful EV-to-EBIT only.
WAT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 16.2 Max: 23.6
Current: 20.03
8.1
23.6
EV-to-EBITDA 17.31
WAT's EV-to-EBITDA is ranked higher than
51% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. WAT: 17.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
WAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7  Med: 14.1 Max: 20.6
Current: 17.31
7
20.6
PEG 3.84
WAT's PEG is ranked lower than
68% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.07 vs. WAT: 3.84 )
Ranked among companies with meaningful PEG only.
WAT' s PEG Range Over the Past 10 Years
Min: 0.58  Med: 1.59 Max: 4.31
Current: 3.84
0.58
4.31
Shiller P/E 34.67
WAT's Shiller P/E is ranked higher than
63% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. WAT: 34.67 )
Ranked among companies with meaningful Shiller P/E only.
WAT' s Shiller P/E Range Over the Past 10 Years
Min: 16.64  Med: 29.9 Max: 51.34
Current: 34.67
16.64
51.34
Current Ratio 6.52
WAT's Current Ratio is ranked higher than
89% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. WAT: 6.52 )
Ranked among companies with meaningful Current Ratio only.
WAT' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.89 Max: 6.52
Current: 6.52
1.19
6.52
Quick Ratio 5.97
WAT's Quick Ratio is ranked higher than
90% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. WAT: 5.97 )
Ranked among companies with meaningful Quick Ratio only.
WAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.54 Max: 5.97
Current: 5.97
0.74
5.97
Days Inventory 117.27
WAT's Days Inventory is ranked higher than
55% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. WAT: 117.27 )
Ranked among companies with meaningful Days Inventory only.
WAT' s Days Inventory Range Over the Past 10 Years
Min: 96.3  Med: 107.44 Max: 117.27
Current: 117.27
96.3
117.27
Days Sales Outstanding 77.55
WAT's Days Sales Outstanding is ranked lower than
72% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. WAT: 77.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
WAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.61  Med: 79.15 Max: 83.7
Current: 77.55
67.61
83.7
Days Payable 27.86
WAT's Days Payable is ranked lower than
83% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. WAT: 27.86 )
Ranked among companies with meaningful Days Payable only.
WAT' s Days Payable Range Over the Past 10 Years
Min: 26.08  Med: 29.67 Max: 35.98
Current: 27.86
26.08
35.98

Buy Back

vs
industry
vs
history
Yield on cost (5-Year) 0.10
WAT's Yield on cost (5-Year) is ranked lower than
96% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. WAT: 0.10 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
WAT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.1
3-Year Average Share Buyback Ratio 2.00
WAT's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. WAT: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 2.4 Max: 6.3
Current: 2
-3.1
6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 42.38
WAT's Price/Net Cash is ranked lower than
76% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.23 vs. WAT: 42.38 )
Ranked among companies with meaningful Price/Net Cash only.
WAT' s Price/Net Cash Range Over the Past 10 Years
Min: 37.61  Med: 99.44 Max: 401.52
Current: 42.38
37.61
401.52
Price/Net Current Asset Value 11.53
WAT's Price/Net Current Asset Value is ranked lower than
62% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. WAT: 11.53 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
WAT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 9.08  Med: 17.45 Max: 310.33
Current: 11.53
9.08
310.33
Price/Tangible Book 8.08
WAT's Price/Tangible Book is ranked lower than
72% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. WAT: 8.08 )
Ranked among companies with meaningful Price/Tangible Book only.
WAT' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.37  Med: 11.98 Max: 1545.29
Current: 8.08
6.37
1545.29
Price/Projected FCF 2.08
WAT's Price/Projected FCF is ranked lower than
56% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. WAT: 2.08 )
Ranked among companies with meaningful Price/Projected FCF only.
WAT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.65 Max: 11.02
Current: 2.08
0.87
11.02
Price/DCF (Earnings Based) 1.55
WAT's Price/DCF (Earnings Based) is ranked higher than
71% of the 17 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.08 vs. WAT: 1.55 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.40
WAT's Price/Median PS Value is ranked lower than
65% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. WAT: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
WAT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.98 Max: 3.53
Current: 1.4
0.24
3.53
Price/Peter Lynch Fair Value 4.26
WAT's Price/Peter Lynch Fair Value is ranked lower than
79% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.22 vs. WAT: 4.26 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
WAT' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.65  Med: 1.61 Max: 5.81
Current: 4.26
0.65
5.81
Price/Graham Number 3.09
WAT's Price/Graham Number is ranked lower than
57% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. WAT: 3.09 )
Ranked among companies with meaningful Price/Graham Number only.
WAT' s Price/Graham Number Range Over the Past 10 Years
Min: 2.34  Med: 3.38 Max: 49.57
Current: 3.09
2.34
49.57
Earnings Yield (Greenblatt) (%) 5.02
WAT's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. WAT: 5.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
WAT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.2  Med: 6.2 Max: 12.4
Current: 5.02
4.2
12.4
Forward Rate of Return (Yacktman) (%) 9.26
WAT's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. WAT: 9.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
WAT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 9.2  Med: 15.8 Max: 26.3
Current: 9.26
9.2
26.3

More Statistics

Revenue (TTM) (Mil) $2,099
EPS (TTM) $ 5.95
Beta0.85
Short Percentage of Float3.98%
52-Week Range $112.00 - 162.53
Shares Outstanding (Mil)80.57

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,177 2,296 2,439
EPS ($) 6.49 7.13 7.85
EPS w/o NRI ($) 6.49 7.13 7.85
EPS Growth Rate
(3Y to 5Y Estimate)
7.66%
Dividends Per Share ($)
» More Articles for NYSE:WAT

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlights Aug 23 2016 
Eugene Cassis Sells Waters Corp. Aug 02 2016 
Companies Hit 52-Week Highs Jul 19 2016 
My Favorite Health Care Stocks Jul 12 2016 
5 Companies Hit Their 52-Week Highs May 31 2016 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Weekly Insider Sells Highlights: Walgreens Boots Alliance, Waters, Fitbit, Extra Space Storage Nov 24 2015 
Weekly Insider Sells Highlight: WAT, KO, GILD, AZO, MAS Dec 14 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
Our Investment Strategy and Portfolio Selection Nov 09 2014 

More From Other Websites
Waters Corp. breached its 50 day moving average in a Bearish Manner : WAT-US : September 30, 2016 Sep 30 2016
Waters Corp. – Value Analysis (NYSE:WAT) : September 19, 2016 Sep 19 2016
Waters Advances Proteomics and Lipidomics Research with Novel Mass Spectrometry Acquisition Mode Sep 19 2016
Waters Advances Proteomics and Lipidomics Research with Novel Mass Spectrometry Acquisition Mode Sep 19 2016
Waters Corp. breached its 50 day moving average in a Bullish Manner : WAT-US : September 16, 2016 Sep 16 2016
Waters Corporation Commentary at the Morgan Stanley Global Healthcare Conference to be Audio Webcast... Sep 08 2016
Waters and NIBRT Researchers Generate Reference Library for Released N-Glycans Labeled with... Aug 23 2016
Waters and NIBRT Researchers Generate Reference Library for Released N-Glycans Labeled with... Aug 23 2016
Water Corp.'s Pharma Business Accelerates Growth Momentum Aug 22 2016
SEC cracks down on made-up numbers in company earnings Aug 19 2016
Waters Expands Microscale Separations Science Portfolio Aug 17 2016
Waters Expands Microscale Separations Science Portfolio Aug 17 2016
Waters Recognizes Dr. Sunghwan Kim of Kyungpook National University Aug 16 2016
Waters Recognizes Dr. Sunghwan Kim of Kyungpook National University Aug 16 2016
Waters Recognizes Dr. Sunghwan Kim of Kyungpook National University Aug 16 2016
VICAM’s Afla-V AQUA Strip Test Receives USDA-GIPSA Certification for the Quantitative Analysis of... Aug 15 2016
WATERS CORP /DE/ Financials Aug 12 2016
Presidential Election Will Set Energy Policy For A Generation Aug 08 2016
WATERS CORP /DE/ Files SEC form 10-Q, Quarterly Report Aug 05 2016
Waterco Ltd. :WAT-AU: Earnings Analysis: For the six months ended December 31, 2015 : August 4, 2016 Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)